GB2353471A - Composition for treating obesity - Google Patents
Composition for treating obesity Download PDFInfo
- Publication number
- GB2353471A GB2353471A GB9915742A GB9915742A GB2353471A GB 2353471 A GB2353471 A GB 2353471A GB 9915742 A GB9915742 A GB 9915742A GB 9915742 A GB9915742 A GB 9915742A GB 2353471 A GB2353471 A GB 2353471A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- nutritional
- patient
- food
- style
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000008589 Obesity Diseases 0.000 title claims abstract description 15
- 235000020824 obesity Nutrition 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 38
- 235000014121 butter Nutrition 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- 239000011575 calcium Substances 0.000 claims abstract description 6
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 6
- 230000001054 cortical effect Effects 0.000 claims abstract description 6
- 230000005284 excitation Effects 0.000 claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 230000004060 metabolic process Effects 0.000 claims abstract description 6
- 235000013343 vitamin Nutrition 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 5
- 239000011782 vitamin Substances 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims abstract description 5
- 235000001465 calcium Nutrition 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 3
- 239000002540 palm oil Substances 0.000 claims abstract description 3
- 235000001014 amino acid Nutrition 0.000 claims abstract 4
- 239000005445 natural material Substances 0.000 claims abstract 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract 4
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 2
- 235000004279 alanine Nutrition 0.000 claims abstract 2
- 235000021391 short chain fatty acids Nutrition 0.000 claims abstract 2
- 235000013305 food Nutrition 0.000 claims description 28
- 235000016709 nutrition Nutrition 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 12
- 235000019197 fats Nutrition 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 235000021152 breakfast Nutrition 0.000 claims description 7
- 235000003642 hunger Nutrition 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 5
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 235000019737 Animal fat Nutrition 0.000 claims description 2
- 240000007124 Brassica oleracea Species 0.000 claims description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 2
- 244000000626 Daucus carota Species 0.000 claims description 2
- 235000002767 Daucus carota Nutrition 0.000 claims description 2
- 241000353541 Heterophoma adonidis Species 0.000 claims description 2
- 235000002791 Panax Nutrition 0.000 claims description 2
- 241000208343 Panax Species 0.000 claims description 2
- 238000011861 anti-inflammatory therapy Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001671 psychotherapy Methods 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 238000009256 replacement therapy Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 206010042008 Stereotypy Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000019488 nut oil Nutrition 0.000 claims 1
- 239000010466 nut oil Substances 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000003240 coconut oil Substances 0.000 abstract description 2
- 235000019864 coconut oil Nutrition 0.000 abstract description 2
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 abstract 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 abstract 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 abstract 1
- 229930003270 Vitamin B Natural products 0.000 abstract 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 abstract 1
- 229940095618 calcium glycerophosphate Drugs 0.000 abstract 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract 1
- 235000019341 magnesium sulphate Nutrition 0.000 abstract 1
- 235000007715 potassium iodide Nutrition 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Inorganic materials [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 abstract 1
- 235000009518 sodium iodide Nutrition 0.000 abstract 1
- 235000019156 vitamin B Nutrition 0.000 abstract 1
- 239000011720 vitamin B Substances 0.000 abstract 1
- 230000035882 stress Effects 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 206010033307 Overweight Diseases 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000218996 Passiflora Species 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 235000017468 valeriana Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A composition for correction of impaired metabolism, and in particular for treating obesity and related disorders comprising natural substances for restoring balance in processes of excitation and cortical inhibition, amino acid, source of short chain fatty acids, calcium, and vitamin. The ingredients specifically mentioned include : <SL> <LI>(a) natural substances : extracts of <U>Adonidis vernalis</U> and <U>Leonuri sp.</U> , sodium or potassium bromide, magnesium sulphate and sodium or potassium iodide : <LI>(b) amino-acid : alanine ; <LI>(c) short chain fatty acid : butter, coconut oil or palm oil ; <LI>(d) calcium : calcium dihydromonophosphate or calcium glycerophosphate ; <LI>(e) vitamin : vitamin B<SB>6</SB>. </SL>
Description
Composition for treating obesity and related disorders and using thereof
The present invention relates to a novel composition useful for correction of impaired metabolism, and in particular for treating obesity and related disorders. The invention further relates to the use of the novel composition for the prevention or treatment of weight gain in a human organism in need of such prevention or treatment. The said composition may be also used for the treatment of some neurological conditions characterized by impaired balance in processes excitation and cortical inhibition.
The problems of weight control, in particular normalization of the accumulation of fat, has long been an issue of concern.
According to the WHO presentation (Feature N190, March 1996) obesity, or overweight, together with smoking, stressful environment, excessive alcohol consumption and lack of physical activity form a group of lifestyle risk factors associated with increased morbidity and mortality from noncommunicable diseases, so that by the year 2020, they will account for about three-quarters of all deaths in the developing world. On the other hand, in many cases they are preventable.
According to the WHO estimation, up to 20% of Europeans and of whites in the US between 20 to 60 years of age are grade 2 overweight. This figure increases up to 40% for women in eastern European and Mediterranean countries and black women in the US. Up to 70 % of women on the island of Nauru in Micronesia are grade 2 overweight, while in India it is only 3 %.
At the same document it is claimed that more often than not, obesity is the result of unhealthy eating habits coupled with a sedentary way of life.
A reduction in caloric intake has long been used as an attempted treatment for obesity. Accordingly, absolute majority of the known compositions for prevention and treatment of obesity has as its goal to suppress appetite.
However, it is well documented that reduction in caloric intake soon reduces metabolic rate, which causes weight loss to slow down and even stop. Furthermore, after the caloric reduction is discontinued and an unrestricted diet is resumed, the slower metabolic rate causes rapid weight gain. As a result, most attempts at weight control through caloric restriction are unsuccessful or only moderately successful and any benefit is short lived (US Patent 5,760,047).
a 00 00 0 0 0 0 to During previous every day practice we were surprised that our recommended diet was more rich in calories than basic one used by our patients, and nevertheless about 60% of the patients had lost the weight successfully. In that cases the assortment of the food in recommended diet was quite different from basic one. Currently in order to understand the said process we recommended to our obese patients during 3 to 7 days to register food intake by items, quantity, time and place, and to weight themselves and to measure some circumferences. During the next period up to 3 weeks they ate according to the same plan, but from about 1.5 to about 2 times more food. The great majority of patients subjected to this procedure did not change neither their weight nor circumferences. About 5% of the patients from the first days started to lose weight. About 20% of the patients during the first week, or so, gained their weight from about 1 to about 6 kg. But keeping the same diet plan all of them during the next 2 weeks returned back to initial weight or had lost some kilograms in comparison to initial weight. From this observation we concluded that energy intake does not affect body fat content. On the other hand, both psychic and physiologic aspects of hunger play their role in converting metabolism to thrifty type. From this point of view it is very important not only to intake enough amount of all kinds of nutrients, but also to destroy stereotype of the hungry diet plan.
In the most of our patients impaired balance in processes excitation and cortical inhibition was diagnosed. Correction of the said balance improved both the condition of patients and the outcome in losing weight.
On the other hand, in our observations the stress was the most important of the decreasing success factors. Furthermore stress is the most important factor hindering to maintain successful result. We use the term "stress" as reactions of the body to forces of a deleterious nature, infections, and various abnormal states that tend to disturb its normal physiologic equilibrium (homeostasis). Sometimes any kind of stress may appear as only one reason of the obesity.
Activation of gluconeogenesis is used as one of the basic activity of the disclosed composition. This reaction is achieved by presenting excessive amount of the amino-acid, preferable I-alanine, in the composition. It is known, that by this way gluconeogenesis can by activated only in the starvation, otherwise amino-acid must be utilized alongside the release of energy or for protein construction. From one hand, the presence in the composition of substances for restoring balance in processes of excitation and cortical inhibition, and, from the other hand, of both calcium (preferable as calcii dihydromonophosphat, but also possible as calcii chiconatis, calcii glycerophosphatis or combination thereof) and vitamin B6 (preferable in combination with other vitamins of group B) allows to activate gluconeogenesis in any amount without starvation.
According to our clinical observation animal fats (first of all butter) play an important role for losing weight by the disclosed method. Supposedly, the role of butter depends on short- and middle-chain fattyacids. It is possible to use plant oil, for example coconut oil, palm oil or combination thereof, but in the disclosed method animal sources of the fatty-acids are preferable. Modern technology of the butter includes the usage of some artificial substances in many countries. Sometimes, it is dangerous, and diminishes therapeutic result. So, in order to obtain independence from source of the butter, high quality butter is included in the composition.
It is ascertained empirically that combination of extractum herbae Adonidis vernalis, extractum herbae Leonuri, natrii or ka1ii bromidum, magnesii sulfatis, and natrii or ka1ii iodidum, further comprising caffenum provide the high effective normalization of the said balance in the obese patients. It is more effective, than combination with Passiflora, and does not irritate the intestine in comparison to Valeriana. The next proportion provides the best result: for each I g of Extracturn h. Adonidis vernalis (1:1): Extractum h. Leonuri (1:1) from about 1.3 to about 7 g; Natrii bromidi from about 0.8 to about 3 g; Natrii iodidi from about 0.01 to about 0.3 g; Magnesii sulfatis from about 0.1 to about 0.6 g. It is reasonable to add plant extracts chosen from Panax ginzeng, Shizandra, Ehinophanaps, Eleuteraoccus, or combination thereof in individual cases.
Chemical incompatibility of some ingredients may be eliminated by micro encapsulation of the ingredients.
The said composition may be produced as pharmaceuticals with a pharmaceutically acceptable carrier or excipient, or as food supplement as well.
Composition disclosed herein allows to obtain the good result in normalizing the impaired metabolism in obese person only in the frame of the disclosed method of using thereof.
In order to predict the effectiveness of the disclosed method for any individual patient, and, if possible, to avoid any circumstances which can low the said effectiveness before the treatment by disclosed composition, some tests must be provided. Hypersensitivity to any food may be the only cause of the obesity. So, it must be tested by any kit, or by any method used in the clinical practice. If hypersensitivity to any food is revealed, hyposensibilisation by very small doses must be done. In the unforturi,ate result such 00 0 0 4,:00.00.0.
04.0 soso food must be eliminated. On the other hand, sometimes endocrine pathology may take place. In such cases hormonal replacement or anti -inflammatory therapy must precede the treatment by the said composition.
In order to plan correct scheme of treatment by the disclosed composition it is reasonable to diagnose the metabolic disorders causing the obesity in the patient, and determine the importance of etiologic factors in an individual patient. One of the ways to solve this problem is to subject the patient to some nutritional tests. For example, to use some monodiets with excessive amount of one nutrients in comparison to the others, and to evaluate the response on anthropometric feature (like loosing and regaining weight), and the patient's feeling (like duration after meals before hunger, headache, aftertastes, weakness, sickness.
Usage of the said composition may be successful only in combination with some elements of life style.
All food must be only natural one. It means the food must be prepared only from traditional food raw materials without any chemical treatment. Furthermore, the said food must be traditional one for an individual patient. Otherwise, the food causes the stress. In order to avoid nutritional stress the food must be tasteful, rich enough in energy, corresponding to the appetite, and the number of the food intake per day must be constant (from 3 to 6, as a rule 4 times a day). Nutrition must be seasonal one. Methods of the food preservation must be very limited by the condition that the treatment must be so safe that new chemical substances or isomers do not appear, excluding those that are a result of traditional for food production microorganisms activity. For prevention of the stress from food monotony phases of nutrition must be interchanged. The fat intake must be no less than 30 g per day, animal fat should be no less than 70% of the whole fat, and the butter should be no less than 30% of the whole fat, furthermore, as a source of essential lipids, in average at least I egg must be taken. The sources of the fat and oil must be only natural food raw materials. Excessive quantity of plant oil causes instability of the cell membranes.
In order to eleminate stress of non-nutrition factors sound therapy, psychotherapy, games and plays, collective entertainment, or combination thereof may be used.
Combination of the foodstuffs depends only on nutrients content. Pharmacologic actions of food obtained by excesses of one foodstuff in comparison to another are not used, because it may be additional sources of the metabolic stress.
so: 0 0 0000 0: " 0 0 On the other hand excessive amount of the natural metabolites in combinations with special elements of lifestyle may be used in the frame of the said method, for example, I-alanine of recipe may be combined with injections of glucagon and the walking in special tempo, so that the tempo of the walk would be accelerating gradually up to the tempo when the further acceleration would caused the pant, duration of the said walk must be no less than about 40 minutes including no less than about 30 minutes in the high tempo.
In order to create optimal streams of the nutrients an interval between meals must be depending on the food, but never should be less than 2.5 hours, because of cyclic nature of the stomach activity. Before breakfast must be taken carrot or cabbage juice. The breakfast must consist of the foods supplying by large amount of the energy immediately, and the said breakfast must follow no more than about 30 minutes after getting up, because in normal condition after night rest there is not enough energy to wake the organism up. As alternative to this principle of the building breakfast, meat products can be used. Lunch must be preferably rich in the fiber in order to obtain carrier for ingestion nutrients little by little during the day, for example, the breakfast may consist of the raw vegetables snacks with high content of the fiber. In the evening to eat less than 4 hours before going to bed must be avoid. The meals must be rich in protein, and poor in fiber, in order to avoid both excess of the energy in the night and the stereotype of hunger. In order to avoid stress during the early stages this meal may comprised from boiled vegetables.
Among obese people absolute majority patients have no full block of one or another metabolic way, but only limited pathway. So, if on the background of rich diet, while depots are rich, to use short period of the monodiet from time to time, for example, only apple juice during a day, or only yogurt during a day, -the number of the active pathways is much less than usually. It can give to the body possibility to organize the way in need much more effective.
Claims (32)
1. A composition for prevention or treatment the obesity or related diseases including at least one natural substance for restoring balance in processes of excitation and cortical inhibition, at least one amino acid, source of short chain fatty acids, source of calcium, at least one vitamin, and at least one mineral.
2. The composition of claim 1, wherein sources of the said natural substances for restoring balance in processes of excitation and cortical inhibition are extractum herbae Adonidis vernalis, extractum herbae Leonitri, natrii or kalff bromidum, magnesii sulfatis, and natrii or kaIii iodidum.
3. The composition of claim 2, comprising for each 1 g of Extractilm h. Adonidis vernalis (1:1): Extractum h. Leonuri (1:1) from about 1.3 to about 7 g; Natrii bromidi from about 0.8 to about 3 g; Natrii iodidi from about 0.01 to about 0.3 g; Magnesii sulfatis from about 0. 1 to about 0. 6 g.
4. The composition of claim 2 or 3, further comprising natural source of caffeine.
5. The composition of claim 2, 3, or 4, further comprising a pharmaceutically acceptable form of plant selected from the group consisting of Panax ginzeng, Shizandra, Ehinophanaps, Eleuteraoccus, or combination thereof.
6. The composition of claim 1, wherein the said aminoacid is alanine.
7. The composition of claim 1, wherein the said source of short chain fat acids is selected from the group consisting butter, cocco nut oil, palm oil or combination thereof.
8. The composition of claim 1, wherein the said source of calcium is selected from the group consisting calchim dihydromonophospat, calcii cluconatis, calcii glycerophosphatis or combination thereof.
9. The composition of claim 1, wherein the said vitamin is vitamin B6.
10. The composition of claim 1, wherein the chemical compatibility of said composition being achieved due to the microencapsulation of its components.
11. The formula of claim 1, wherein the said composition is in a feed.
12. The formula of claim 1, wherein the said composition is administrated with a pharmaceutically acceptable carrier or excipient.
13. A method of treatment obesity by using the composition of claim I or 4 comprising of:
- prediction of the effectiveness of the said method for an individual patient, and, if possible, the clearance of any agent which can lower the said effectiveness; - diagnostic of the metabolic disorders causing the obesity in the patient, and determination of the importance of etiologic factors in the said patient; - prescription of the formula of claim 1; destruction of the chronic hunger and food limitation stereotype; providing actions for the stress relief in the patient; - determining that the said patient has used only natural and rich in nutrients food, furthemore the foodstuffs have to be combined according to nutritive peculiarity; - instructing the said patient regarding the style of nutrition; - using for the repair of metabolism interaction the excessive amount of natural metabolites, from one hand, and elements of lifestyle, on the other hand; - using monodiets.
14. A method of claim 13, wherein for prediction of the effectiveness of the said method for an individual patient, and, if possible, the clearance of any agent which can lower the said effectiveness, hypersensitivity to foodstuffs is diagnosed and, if the result is positive, hyposensitization is taken, and if the result cannot be achieved, such foodstuffs are eliminated form nutritional plan.
15. A:method of claim 13, wherein for prediction of the effectiveness of the said method for an individual patient, and, if possible, the clearance of any agent which can lower said effectiveness, the said patient is subjected to medical examination in order to evaluate endocrine disorders, and to correct it by hormonal replacement or anti - inflammatory therapy.
16. A method of claim 13, wherein for diagnostic of the metabolic disorders causing the obesity in the patient, and determination of the role of etiologic factors in the said patient, nutritional tests are evaluated.
17. A method of claim 16, wherein as nutritional tests monodiets with excessive amount of one nutrients in comparison to the others are used, and the response on anthropometric feature and the patient's feeling.
18. A method of claim 13, wherein the said destruction of the chronic hunger and food limitation stereotypy being by nutritional recording during from 3 to 7 days, and than the patient being instructed to eat quite the same as in nutritional records, but from about 1.5 to abour 2 times more, and anthropometric features being registrated during all the said period;
19. A method of claim 13, wherein providing actions for the stress relief in the patient by sound therapy, or by psychotherapy, or by games and plays, or collective entertainment, or combination thereof is beimg used.
20. A method of claim 13, wherein for prevention of the stress from food monotony phases of nutrition are interchanged.
21. A method of claim 13, wherein for prevention of the nutritional stress, only the usual food for an individual patient is used.
22. A method of claim 13, wherein for prevention of the nutritional stress, the food for an individual patient is being selected from the natural food so that it is as much pleasurable for him, as possible.
23. A method of claim 13, wherein as one of the elements of nutritional style being from 3 to 6 serving a day, preferable 4, and this number must be the same day by day.
24. A method of claim 13, wherein as one of the elements of nutritional style an interval between meals depends on food, but never appears less than 2.5 hours.
25. A method of claim 13, wherein as one of the elements of nutritional style, assortiment of the food being chosen from all the natural foodstuffs according to appetite, so as fat intake was no less than 30 g per day, animal fat would be no less than 70% of the whole fat, and the butter would be no less than 30% of the whole fat, furthermore, as a source of essential lipids, in average of at least I egg must be taken.
26. A method of claim 13, wherein as one of the elements of nutritional style, as juice of cabbage or carrot or their combination being used in the morning before meals.
I 0 0%. I I
27. A method of claim 13, wherein, as one of the elements of nutritional style, breakfast consists of the foods supplying large amount of the energy immediately, and the said breakfast must folow no more than about 30 minutes after getting up.
28. A method of claim 13, wherein, as one of the elements of nutritional style, lunch should preferably consist of the raw vegetables snacks whith the high content of fiber.
29. A method of claim 13, wherein, as one of the elements of nutritional style, dinner preferably consist of the high protein of animal food.
30. A method of claim 13, wherein, as one of the elements of nutritional style, the last serving being no less than about 4 hours before going to bed.
3 1. A method of claim 13, wherein, as one of the elements of nutritional style, quantity of the food id determined by appetite exclusively.
32. A method of claim 13, wherein, as using for the reparing of metabolism interaction of the excessive amount of natural metabolites, from one hand, and elements of life style on the other hand, subjecting the said patient to the long walk after I-alanine and glucagone intake, so that tempo of the walk would be accelerating gradually up to the tempo when the further accelerating would cause the pant, duration of the said walk must be no less than about 40 minutes including no less than about 30 minutes in the high tempo.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9915742A GB2353471B (en) | 1999-07-06 | 1999-07-06 | Composition for treating obesity and related disorders and using therof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9915742A GB2353471B (en) | 1999-07-06 | 1999-07-06 | Composition for treating obesity and related disorders and using therof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9915742D0 GB9915742D0 (en) | 1999-09-08 |
| GB2353471A true GB2353471A (en) | 2001-02-28 |
| GB2353471B GB2353471B (en) | 2004-08-18 |
Family
ID=10856693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9915742A Expired - Fee Related GB2353471B (en) | 1999-07-06 | 1999-07-06 | Composition for treating obesity and related disorders and using therof |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2353471B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003090557A1 (en) * | 2002-04-24 | 2003-11-06 | The Procter & Gamble Company | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| EP1474998A1 (en) * | 2003-05-05 | 2004-11-10 | Dietetic S.P.A | Composition useful for weight control |
| WO2007031291A3 (en) * | 2005-09-14 | 2007-05-10 | Mark Warnecke | Foodstuff additive |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1493993A (en) * | 1975-05-16 | 1977-12-07 | Howard A | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
| WO1996039053A2 (en) * | 1995-06-06 | 1996-12-12 | Campbell Soup Company | Mineral supplements for dietetic food |
-
1999
- 1999-07-06 GB GB9915742A patent/GB2353471B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1493993A (en) * | 1975-05-16 | 1977-12-07 | Howard A | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
| WO1996039053A2 (en) * | 1995-06-06 | 1996-12-12 | Campbell Soup Company | Mineral supplements for dietetic food |
Non-Patent Citations (1)
| Title |
|---|
| Abstracts of JP 3290157 A (Terumo Corp.) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003090557A1 (en) * | 2002-04-24 | 2003-11-06 | The Procter & Gamble Company | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| EP1474998A1 (en) * | 2003-05-05 | 2004-11-10 | Dietetic S.P.A | Composition useful for weight control |
| WO2007031291A3 (en) * | 2005-09-14 | 2007-05-10 | Mark Warnecke | Foodstuff additive |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9915742D0 (en) | 1999-09-08 |
| GB2353471B (en) | 2004-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6413545B1 (en) | Diet composition and method of weight management | |
| World Health Organization et al. | Keep fit for life: meeting the nutritional needs of older persons | |
| Hickson | Malnutrition and ageing: This article is part of a series on ageing edited by Professor Chris Bulpitt | |
| Volkert | The role of nutrition in the prevention of sarcopenia | |
| Wolfe et al. | Replacement of carbohydrate by protein in conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects | |
| Singh | Journal of Nutrition & Food Sciences | |
| US20160374941A1 (en) | Chewing Gum with Tomatidine | |
| JP5775668B2 (en) | Anti-fatigue agent containing amino acid composition | |
| CN112739222A (en) | Anti-aging agent and anti-aging method | |
| JP2006510367A (en) | Blood sugar regulating composition | |
| JP2021502064A (en) | How to choose probiotics | |
| Mudambi | Fundamentals of foods and nutrition | |
| Begum | A textbook of foods, Nutrition & Dietetics | |
| ATTARZADEH et al. | A review of the effects of Ramadan fasting and regular physical activity on metabolic syndrome indices | |
| Erdmann et al. | Amino Revolution | |
| Kourkouta et al. | Nutritional habits in the elderly | |
| GB2353471A (en) | Composition for treating obesity | |
| MX2013011144A (en) | TRMP5 INHIBITORS THAT HELP THE REDUCTION OF BODY WEIGHT WITHOUT REDUCING FOOD INGESTION. | |
| WO2017176199A1 (en) | A macronutrient composition for use in a method for treatment of gestational diabetes | |
| FR3106957A1 (en) | DIETARY COMPOSITION TO STIMULATE COGNITIVE FUNCTION AND PREVENT AND LIMIT COGNITIVE DECLINE AND Dementia in ADULT SUBJECTS OR IN SUBJECTS AGED WITH DENUTRIES | |
| Balch | Prescription for nutritional healing: The A-to-Z guide to supplements | |
| WO2019130167A1 (en) | Composition for use in the treatment of malabsorption secondary to bariatric surgery | |
| EP1592433B1 (en) | Sexual desire and performance enhancement with meal from plants containing protein-bound tryptophan | |
| Babilas | Nutritional diseases | |
| US6638541B1 (en) | Sexual desire and performance enhancement with protein-bound tryptophan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20041118 |